Published in Drug Week, September 18th, 2009
This is the first time a study evaluating the combination therapy, peginterferon and ribavirin, has identified sexual dysfunction as a side effect. Sexual dysfunction and impairment of desire should be considered common side effects of combination antiviral therapy in men with hepatitis C. It has the potential to affect all three components of sexual health: desire, function and satisfaction.
Before therapy, 37 percent of men...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2009-09-18)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.